Pharmacokinetic Predictor of Infection in Patients With Inflammatory Bowel Disease Treated With Intravenous and Subcutaneous Infliximab.
INTRODUCTION Infliximab (IFX) has significantly improved outcomes for patients with inflammatory bowel disease (IBD) but also predisposes them to infection. Preinfusion trough concentration (Ctrough) is commonly used in therapeutic drug monitoring (TDM) to optimize IFX efficacy. However, reliable pharmacokinetic (PK) o...